Empliciti (elotuzumab) / AbbVie, BMS - LARVOL DELTA

CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure (IMS 2026) - P3 | "Pts were randomized 1:1 to Etenta Q4W or SAT (carfilzomib + dexamethasone [Kd], elotuzumab + pomalidomide + d [EloPd], or selinexor + bortezomib + d [SVd]). In heavily pretreated pts with triple-class exposed RRMM, Etenta significantly improved ORR and PFS vs SAT, with an early positive OS signal. A single SUD andQ4Wdosing from initiation were associated with very low rates of CRS, ICANS, and ≥ G3 infections, reinforcing Etenta’s best-in-class safety potential. Data support Etenta monotherapy as a new standard of care with convenient dosing suitable for global outpatient and community use."

Clinical • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Open-Label, Single-Arm Phase Ib/Ii Study of Immune Combination Therapy with Belantamab Mafodotin and Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P1/2 | "The combination immune therapy of belantamab mafodotin and elotuzumab appears to have an encouraging safety profile and a promising activity in patients with heavily pretreated RRMM, including in those with prior failure of BCMA-targeted T-cell redirection therapy. Funding and Product for this study was provided by GSK NCT05002816 ."

Clinical • Combination therapy • P1/2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Ophthalmology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Immunomodulatory Salvage Reverses Primary Refractoriness to Bispecific T-Cell Engagers in Multiple Myeloma (IMS 2026) - " We report five patients (pts) with RRMM treated between 2023 and 2026 in three tertiary cancer centers who were primarily refractory or have shown progressive disease after at least one full cycle of teclistamab (n=2) or talquetamab (n=3). All 5 pts received immunomodulatory salvage with pomalidomide (POM) added to ongoing TCE therapy (POM mono, n=2) or initiated shortly after TCE discontinuation (daratumumab(DARA)-POM-cyclophosphamide(CY)-dexamethasone(dex), n=1; POM-CY-dex, n=1; elotuzumab-POM-dex, n=1)... Response depth and kinetics exceeded what is expected from used salvage regimens alone. Persistent TCE concentrations after discontinuation together with POM-based salvage led to a de facto combination therapy. This combination was able to reverse functional TCE resistance, even in pts refractory to the salvage drugs."

Bispecific • Immunomodulating • Hematological Malignancies • Multiple Myeloma • CD38 • CD4 • CD8 • IKZF1 • IKZF3 • IL2 • TIGIT

Comparative Efficacy of Elotuzumab, Pomalidomide, and Dexamethasone vs Standard Care Triplets in Relapsed/Refractory Multiple Myeloma After at Least One Prior Line of Therapy: A Network Meta-Analysis (IMS 2026) - "Assuming equivalence ( collapsed node s ) between pomalidomide – dexamethasone (Pd) and bortezomib – dexamethasone ( Vd ), and between carfilzomib – dexamethasone ( Kd ) and lenalidomide – dexamethasone (Rd), EPd showed no statistically significant difference in PFS versus any of the eight comparator triplet regimens ; HRs ( 95% CrIs ) ranged from 0.81 ( 0.43 – 1.54 ) versus selinexor – Vd to 1.39 ( 0.69 – 2.85 ) versus daratumumab (D )– Kd , with all CrIs crossing 1. This NMA found no statistically significant differences in PFS between EPd and other approved or guideline-recommended triplet regimens in patients with RRMM with ≥1 prior line of therapy, any prior R exposu re , and no prior anti-CD38 exposure . Results were consistent in the R-refractory sub group across alternative pooled doublet scenarios, supporting EPd as a n appropriate control among SOC options . Ongoing trials including EPd in anti-CD38 – exposed/refractory populations may help further..."

Retrospective data • Hematological Malignancies • Multiple Myeloma

CEVOLUTION: A Randomized Phase III Trial Comparing Cevostamab Plus Pomalidomide and Dexamethasone (Pom-Dex) Versus Standard of Care (SOC) in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - "Introduction: Efficacious new treatments are needed for RRMM patients (pts) with prior anti-CD38 antibody (Ab) and lenalidomide (len) exposure...In Arm B, pts will receive investigator’s choice of either daratumumab plus pom-dex, elotuzumab plus pom-dex or carfilzomib plus dex, with the choice informed by the pts prior treatment exposure and refractoriness to individual classes of agents... CEVOLUTION is a pivotal Phase III trial that is expected to inform the clinical efficacy and safety of cevostamab plus pom-dex in pts with RRMM."

Clinical • P3 data • Hematological Malignancies • Multiple Myeloma

CEVOLUTION: A RANDOMIZED PHASE III TRIAL COMPARING THE EFFICACY AND SAFETY OF CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (EHA 2026) - "Background Anti-CD38 antibodies (Abs), such as daratumumab (dara) and isatuximab, and immunomodulatory drugs (IMiDs), such as lenalidomide (len), are frequently used in the early lines of multiple myeloma (MM) therapy...In Arm B, pts will receive investigator's choice of either dara plus pom-dex, elotuzumab plus pom-dex or carfilzomib plus dex, with the choice informed by the pts prior treatment exposure and refractoriness to individual classes of agents...First patient enrollment is expected in Q2 2026. Summary/Conclusion CEVOLUTION is a pivotal Phase III trial that is expected to inform the clinical efficacy and safety of cevostamab plus pom-dex in pts with RRMM."

Clinical • P3 data • Hematological Malignancies • Multiple Myeloma

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. (PubMed, Lancet Haematol) - P3 | "Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival versus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for HSCT. Although these data contribute to the treatment landscape, further research is needed to find ways to improve treatments in the front-line setting."

Journal • P3 data • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Transplantation

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review (ASH 2023) - "Amongst trials that met primary endpoint showing improvement in PFS and clearly reported on +1q, the following drugs also improved PFS for those with +1q (when comparing hazard ratio (HR) for intervention versus control arm in the +1q subgroup): lenalidomide (len) maintenance in Myeloma XI, selinexor in BOSTON, and isatuximab in IKEMA and ICARIA...These included addition of carfilzomib in Myeloma XI, addition of carfilzomib vs bortezomib to len and dex for +1q (but not in Amp1q) in ENDURANCE, addition of elotuzumab to pomalidomide and dex, and bortezomib-based treatment before and after autologous stem cell transplantation (auto-SCT) vs no bortezomib (Table 2)...Important interventions for which subgroup analysis of +1q was not presented in trial results, and hence conclusions about the efficacy of the drugs specifically for patients with +1q cannot be ascertained included pomalidomide and ixazomib. Although subgroup analysis of various daratumumab trials has shown..."

Clinical • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. (PubMed, Blood) - P1/2, P3 | "We conducted a secondary pooled analysis of the S0777 and S1211 SWOG studies of NDMM, which employed lenalidomide-dexamethasone (Rd) alone with or without bortezomib (VRd) and with or without elotuzumab (Elo-VRd). Given dexamethasone's many toxicities and unclear benefit in the era of modern treatment regimens, dexamethasone dose reduction during NDMM induction warrants further prospective study. NCT00644228, NCT01668719."

Journal • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Insomnia • Multiple Myeloma • Oncology • Sleep Disorder • Thrombocytopenia

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. (ASCO 2023) - P3 | "In this study, the addition of elotuzumab to KRd significantly improved the rate of early, deep (≥ VGPR) MRD-negative remission in TE NDMM. E-KRd pts had slightly more TEAEs. Events were mainly hematotoxicity."

Clinical • P3 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplantation

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. (PubMed, Clin Lymphoma Myeloma Leuk) - "A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations."

Journal • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Novel Coronavirus Disease • Oncology • CD4 • CD8

Ide-cel versus Standard Regimens in Triple-class-Exposed RRMM: Phase 3 KarMMa-3 (EHA-EBMT-CART 2023) - P3 | "Patients were randomized 2:1 to receive ide-cel or a standard regimen (investigator choice of daratumumab/pomalidomide/dexamethasone, daratumumab/bortezomib/dexamethasone, ixazomib/lenalidomide/dexamethasone, carfilzomib/dexamethasone, or elotuzumab/pomalidomide/dexamethasone, based on prior regimen). Lymphodepletion with fludarabine and cyclophosphamide and optional bridging therapy preceded ide-cel infusion (target dose 150-450×106 CAR+ T cells; ≤540×106 cells allowed)... Ide-cel treatment resulted in a significant improvement in PFS and ORR, with deeper and more durable responses than standard regimens. Ide-cel benefit was consistent across difficult-to-treat subgroups. The toxicity profile of ide-cel was consistent with previous studies."

IO biomarker • P3 data • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Multiple Myeloma • Oncology

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. (PubMed, J Clin Oncol) - P2 | "EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly."

Journal • P2 data • Hematological Malignancies • Multiple Myeloma • Oncology

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial (ASH 2023) - P1/2 | "Intravenous (IV; 16 mg/kg) or subcutaneous (1800 mg) DARA was given weekly (C1–2), then biweekly (C3–6), and monthly (≥ C7) for subcohorts B1 and B3, and weekly (C1–3) then on D1 of each 21-D (C4–8) or 28-D (≥ C9) cycle for subcohort B2; with weekly oral/IV DEX (40 mg; 20 mg > 75 y or body mass index < 18.5 kg/m2). MeziDd showed promising efficacy and a manageable safety profile in pts with RRMM and 2–4 prior lines of therapy, as did MeziEd in pts with prior anti-CD38 mAb therapy. The immune activity of MEZI was consistent with previous preclinical reports. Improved safety and efficacy may be achieved by schedule and dose adjustments."

Clinical • Cardiovascular • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Pulmonary Embolism • Respiratory Diseases • Targeted Protein Degradation • Thrombocytopenia • CRBN

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment (ASH 2021) - P1b/2 | "X is approved with bortezomib (V) and dexamethasone (XVd) in patients (pts) with at least 1 prior therapy and is not associated with known long-term clinically significant toxicities such as visual loss, cardiac dysfunction, renal failure, neuropathy, irreversible bone marrow suppression, second malignancies, venous thromboembolism, or rash...Here we report on all pts in STOMP with prior anti-BCMA treatment who were treated on STOMP with X+pomalidomide +dexamethasone (XPd); XVd; X+carfilzomib+d (XKd); XPVd; and XPd+elotuzumab (E) (XPEd). Results In total, 11 pts with prior anti-BCMA therapy (6 pts with belantamab mafodotin; 1 each with MEDI2228, SEA-BCMA, BCMA BITE; 2 with idecabtagene vicleucel) were treated with 5 X-containing regimens (Table 1): 9 pts were treated with triplets XPd (4), XVd (3), or XKd (2) and 2 pts with quadruplets XPVd (1) or XPEd (1)...Conclusions In this follow-up cohort of heavily pretreated pts, a majority of whom with MM refractory to..."

Clinical • Cardiovascular • Hematological Disorders • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology • Pain • Renal Disease • Thrombocytopenia • Venous Thromboembolism

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2–4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial (ASH 2023) - P3 | "The aim of the present study was to analyze the effect of ide-cel versus standard regimens (daratumumab [DARA], pomalidomide, and dexamethasone [DEX]; DARA, bortezomib, and DEX; ixazomib, lenalidomide, and DEX; carfilzomib and DEX; or elotuzumab, pomalidomide, and DEX) on HRQoL in KarMMa-3 trial participants with an extended follow-up of patient-reported outcomes (PRO) data collection (data cutoff date April 28, 2023). In the KarMMa-3 trial, patients with TCE RRMM who had received 2–4 prior regimens, ide-cel significantly and meaningfully improved MM-relevant symptoms, functioning, and overall health status/HRQoL compared with standard regimens. Confirmed HRQoL improvements in the ide-cel arm occurred sooner than standard regimens. PRO improvements were sustained over more than 2 years, which is notable after a single infusion treatment with ide-cel."

Clinical • HEOR • P3 data • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • Oncology • Pulmonary Disease

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant (ASH 2023) - "Of the therapies listed, 6 were adequately available in LIC and HIC: cyclophosphamide, lenalidomide, pomalidomide, daratumumab, bortezomib, and ASCT (Table 1)...Conclusion While most therapies were available, novel therapies such as isatuximab, ixazomib, selinexor, and elotuzumab were less readily accessible...The financial burden on healthcare is a major limiting factor. USMIRC plans to investigate potential solutions and pursue global collaborative efforts to reduce disparities in therapies."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma. (PubMed, Blood Cancer J) - No abstract available

Journal • P2 data • Hematological Malignancies • Multiple Myeloma • Oncology

Combination Strategies Enhance NK Cell Therapy for Multiple Myeloma (MM): Memory-like Differentiation, NKG2A Blockade, and Improved Recognition Via BCMA CAR or MM-Targeting Antibodies (TCT-ASTCT-CIBMTR 2025) - "Human NK cells were adoptively transferred into MM-bearing NSG mice to test ML differentiation, NKG2A blockade (monalizumab, IgG4), and BCMA CAR, or combinations, for pre-clinical activity...To complement these strategies, we tested anti-SLAMF7 mAb (elotuzumab) and BMCA CAR (41BB,CD3z) with ML NK cell differentiation... MM patient blood NK cells are functionally intact, and ML differentiation, NKG2A checkpoint blockade, and use of CAR or MM-targeting mAb to enhance recognition significantly improve NK cell anti-MM attack. However, combinations of these resulted in marked improvements to NK cell control of MM. These combinations for anti-MM NK cellular therapy warrant further study in early phase clinical trials."

IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • HLA-E • IFNG • IL12A • IL15 • IL18 • KLRC1 • NKG2D • SLAMF7

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM) (ASH 2023) - P2 | "Disease was refractory to lenalidomide in all patients, and refractory to both bortezomib and lenalidomide in 3 patients. This is the first ever report combining two different mAbs with dual targeting of CD38 and SLAMF7 in RRMM. The results demonstrate that Isa-EloPD combination is both safe and feasible with high frequency and durability of responses. Despite an anticipated reduction in number, NK cell cytotoxicity remain unaffected with the combination."

IO biomarker • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • SLAMF7

IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3, A PHASE 3 RANDOMIZED CONTROLLED TRIAL (EBMT 2023) - P3 | "Patients were randomized 2:1 to ide-cel or a standard regimen (investigator choice of daratumumab + pomalidomide + dexamethasone, daratumumab + bortezomib + dexamethasone, ixazomib + lenalidomide + dexamethasone, carfilzomib + dexamethasone, or elotuzumab + pomalidomide + dexamethasone based on prior regimen). Ide-cel treatment resulted in a significant improvement in PFS and ORR, with deeper and more durable responses versus standard regimens. Ide-cel benefit was consistent across difficult-to-treat subgroups. The toxicity profile of ide-cel was consistent with prior studies."

Clinical • P3 data • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology

CERVINO: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P3 | N=421 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). (ASCO 2022) - P2 | "Most (80%) received induction therapy with bortezomib or carfilzomib + lenalidomide + dexamethasone, 1 patient had prior ASCT, and 4 received >1 prior line of therapy. CB-derived expanded NK cells plus elotuzumab/lenalidomide combined with Mel200 and ASCT results in excellent and durable hematologic and MRD responses in HRMM patients. Furthermore, PFS and OS rates compare favorably to published outcomes for HRMM patients."

Clinical • P2 data • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation • TP53

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. (PubMed, Cancer Cell) - "We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients with high-risk SMM and performed single-cell RNA and T cell receptor (TCR) sequencing on 149 bone marrow (BM) and peripheral blood (PB) samples from patients and healthy donors (HDs). We show that the similarity of a patient's immune cell composition to that of HDs may have prognostic relevance at diagnosis and after treatment and that the abundance of granzyme K (GZMK) CD8 effector memory T (TEM) cells may be associated with treatment response. Last, we uncover similarities between immune alterations observed in the BM and PB, suggesting that PB-based immune profiling may have diagnostic and prognostic utility."

Biomarker • IO biomarker • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CD8

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. (PubMed, Lancet Haematol) - P1/2 | "In the first randomised study of high-risk multiple myeloma reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, progression-free survival in both study groups exceeded the original statistical assumptions and supports the role for continuous proteasome inhibitors and immunomodulatory drug combination maintenance therapy for this patient population."

Clinical • Journal • P2 data • Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Pain • Transplantation